pDONR223-LYN Citations (2)
Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Nov 24. ():. PubMed Journal
Articles Citing pDONR223-LYN
| Articles |
|---|
| LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, Gonzalez-Angulo AM, Mills GB, Red-Brewer M, Mayer IA, Abramson V, Rizzo M, Kelley MC, Meszoely IM, Arteaga CL. J Clin Invest. 2014 Dec;124(12):5490-502. doi: 10.1172/JCI72573. Epub 2014 Nov 17. PubMed |
| Crystal structure of the SH3 domain of human Lyn non-receptor tyrosine kinase. Berndt S, Gurevich VV, Iverson TM. PLoS One. 2019 Apr 10;14(4):e0215140. doi: 10.1371/journal.pone.0215140. eCollection 2019. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.